09:25 AM EDT, 08/22/2025 (MT Newswires) -- Biohaven ( BHVN ) said in a filing late Thursday that it was informed by the US Food and Drug Administration that an advisory committee meeting is no longer needed on the company's new drug application for troriluzole to treat adults with spinocerebellar ataxia.

The company said the FDA's decision on the application is still expected in Q4.

Shares of the company were up 9% in recent premarket activity Friday.